Corporate Overview
History and Mission
The visionary business builders of Epeius Biotechnologies Corporation share an abiding passion for the pursuit of excellence in science focused sharply on the development of superior medicines for cancer. Founded in 2000, and incubated at The University of Southern California School of Medicine, Epeius Biotech emerged in 2002 as a free standing company with an enviable IP portfolio, a high-value tumor-targeting platform and lead product that has been validated in the crucible of clinical medicine, and revenues beginning in 2006.
Epeius Biotechnologies is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems and high-value oncology products. Credited with innovations ranging from gene discovery, therapeutic designer genes, pathotropic (disease-seeking) targeting, high-performance vector engineering, to advanced GMP & Bioprocess development, Epeius is an acknowledged leader in the field of genetic medicine with an impressive intellectual property estate. Rapid advances in clinical development have provided Epeius with a unique opportunity for early revenues from the exportation and sale of its lead product to the Philippines and reciprocating Southeast Asian countries, thus demonstrating the high-growth potential of an innovative biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.
Key Milestones
2003
Rexin-G is granted Orphan Drug Status from the US FDA for pancreatic cancer
2004
Epeius gains exclusive licensing rights from USC for core biotechnologies
Epeius gains supportive IP rights from BioFocus for tumor-targeting system
2005
Epeius R&D raises the bar for biopharmaceutical production with Rexin-G
2006
Rexin-G is granted Expanded Access by Philippine BFAD; first revenues
2007
Rexin-G gains Registration in the Philippines for “all solid tumors”
Epeius completes US Phase I study, with no dose-limiting toxicities
Rexin-G gains US FDA approval for Advanced Phase I/II Protocols
2008
Epeius gains 2 major patents (US and EU) for targeted gene delivery
Epeius advances Rexin-G in U.S. with a Phase II confirmatory study
Epeius gains Orphan Drug Status from US FDA for 2 more indications
Epeius forms strategic alliance for commercial production of Rexin-G
Epeius completes R&D and pilot studies of 2nd product, Reximmune-C
Core Competencies
Epeius Biotech has emerged, through innovation and research, as a global leader in the development of targeted genetic medicine for cancer. With the validation of its lead product(s) in the clinic, Epeius—and its enabling platform biotechnologies—enjoys sustainable best-of-breed and first-mover advantages, and a strong product pipeline. Additionally, Epeius has established a new state-of-the-art in biopharmaceutical GMP manufacturing, with the commercial development of REXIN-G®, which represents a significant advantage to prospective corporate partners in reaching the global market.
